FDB (First Databank) vs MedAware
This is the clearest statement in the index of the argument between rules and learned models in medication safety, and both sides are represented by a vendor that means it. FDB supplies the drug knowledge sitting under most prescribing systems in the United States, which means most interaction and dose alerts a clinician has ever dismissed were built on its content. MedAware was founded after a child died because a physician picked the wrong drug from a dropdown, an error no interaction rule could catch, and it detects prescriptions that do not fit the patient rather than pairs that do not fit each other. The honest framing is that these are layers, not alternatives. The rules catch the known hazard and generate the override fatigue; the outlier model catches what the rules cannot express and has to earn its alerts against an already exhausted prescriber.
- The drug knowledge underneath most American prescribing systems is this company's content, so its interaction and dose warnings are the baseline against which any additional layer is measured.
- The licensing architecture is clean by design: content is embedded in the customer's own systems, which places hosting, residency and processing questions with the customer rather than with the supplier.
- Its own newer products are framed conservatively, with a prescription agent producing orders explicitly for physician review rather than acting.
- It exists because rules missed the error that killed a child, and it detects prescribing outliers a rule library cannot express, using unsupervised outlier detection over longitudinal patient data.
- The evidence was produced mainly by investigators who do not work for the company, including a Harvard Medical School group, which is rare in this category and rarer still for a machine learning product.
- Integration is named and corroborated by customers rather than asserted, with deployments confirmed inside a health system pharmacy workflow and in ambulatory practice.
Side by Side
| Axis | F FDB (First Databank) |
M MedAware |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
These are complementary layers more often than substitutes: rule based checking catches the known interaction, outlier detection catches the prescription that does not fit the patient, and a hospital running both will still see the majority of its alerts from the rules. Neither vendor publishes a security attestation, trust centre or business associate agreement terms.
MedAware publishes no subgroup performance by age, sex, race, ethnicity, insurance status or site, which is the specific gap for an outlier detection model, since what counts as anomalous varies with the population the model learned from. Neither publishes pricing.